A proteolysis targeting chimera (PROTAC) is a heterobifunctional small molecule composed of two active domains and a linker capable of removing specific unwanted proteins. Rather than acting as a conventional enzyme inhibitor, a PROTAC works by inducing selective intracellular proteolysis. PROTACs consists of two covalently linked protein-binding molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein meant for degradation. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein by the proteasome. Because PROTACs need only to bind their targets with high selectivity (rather than inhibit the target protein's enzymatic activity), there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.
Market Analysis and Insights : Global PROteolysis Targeting Chimera (PROTAC) Market
Due to the COVID-19 pandemic, the global PROteolysis Targeting Chimera (PROTAC) market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period.
Fully considering the economic change by this health crisis, ARV-110 accounting for % of the PROteolysis Targeting Chimera (PROTAC) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.
While Oncology segment is altered to an % CAGR throughout this forecast period.
China PROteolysis Targeting Chimera (PROTAC) market size is valued at US$ million in 2021, while the US and Europe PROteolysis Targeting Chimera (PROTAC) are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.
As for the Europe PROteolysis Targeting Chimera (PROTAC) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of PROteolysis Targeting Chimera (PROTAC) include Arvinas, Kymera, C4 therapeutics, Captor therapeutics, Vividion, Cullgen, Pfizer, Merck and Genentech, etc. In 2021, the global top five players have a share of approximately % in terms of revenue.
Global PROteolysis Targeting Chimera (PROTAC) Scope and Segment
PROteolysis Targeting Chimera (PROTAC) market is segmented by Type and by Application. Players, stakeholders, and other participants in the global PROteolysis Targeting Chimera (PROTAC) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and Forecast by Type and by Application for the period 2017-2028.
1 Study Coverage
1.1 PROteolysis Targeting Chimera (PROTAC) Product Introduction
1.2 Market by Type
1.2.1 Global PROteolysis Targeting Chimera (PROTAC) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 ARV-110
1.2.3 ARV-471
1.2.4 KYM-001
1.2.5 Others
1.3 Market by Application
1.3.1 Global PROteolysis Targeting Chimera (PROTAC) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Oncology
1.3.3 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Estimates and Forecasts 2017-2028
2.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Estimates and Forecasts 2017-2028
2.3 Global PROteolysis Targeting Chimera (PROTAC) Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global PROteolysis Targeting Chimera (PROTAC) Sales by Region
2.4.1 Global PROteolysis Targeting Chimera (PROTAC) Sales by Region (2017-2022)
2.4.2 Global Sales PROteolysis Targeting Chimera (PROTAC) by Region (2023-2028)
2.5 Global PROteolysis Targeting Chimera (PROTAC) Revenue by Region
2.5.1 Global PROteolysis Targeting Chimera (PROTAC) Revenue by Region (2017-2022)
2.5.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global PROteolysis Targeting Chimera (PROTAC) Sales by Manufacturers
3.1.1 Global Top PROteolysis Targeting Chimera (PROTAC) Manufacturers by Sales (2017-2022)
3.1.2 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of PROteolysis Targeting Chimera (PROTAC) in 2021
3.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue by Manufacturers
3.2.1 Global PROteolysis Targeting Chimera (PROTAC) Revenue by Manufacturers (2017-2022)
3.2.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by PROteolysis Targeting Chimera (PROTAC) Revenue in 2021
3.3 Global PROteolysis Targeting Chimera (PROTAC) Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global PROteolysis Targeting Chimera (PROTAC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global PROteolysis Targeting Chimera (PROTAC) Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global PROteolysis Targeting Chimera (PROTAC) Sales by Type
4.1.1 Global PROteolysis Targeting Chimera (PROTAC) Historical Sales by Type (2017-2022)
4.1.2 Global PROteolysis Targeting Chimera (PROTAC) Forecasted Sales by Type (2023-2028)
4.1.3 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2017-2028)
4.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue by Type
4.2.1 Global PROteolysis Targeting Chimera (PROTAC) Historical Revenue by Type (2017-2022)
4.2.2 Global PROteolysis Targeting Chimera (PROTAC) Forecasted Revenue by Type (2023-2028)
4.2.3 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Type (2017-2028)
4.3 Global PROteolysis Targeting Chimera (PROTAC) Price by Type
4.3.1 Global PROteolysis Targeting Chimera (PROTAC) Price by Type (2017-2022)
4.3.2 Global PROteolysis Targeting Chimera (PROTAC) Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global PROteolysis Targeting Chimera (PROTAC) Sales by Application
5.1.1 Global PROteolysis Targeting Chimera (PROTAC) Historical Sales by Application (2017-2022)
5.1.2 Global PROteolysis Targeting Chimera (PROTAC) Forecasted Sales by Application (2023-2028)
5.1.3 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2017-2028)
5.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue by Application
5.2.1 Global PROteolysis Targeting Chimera (PROTAC) Historical Revenue by Application (2017-2022)
5.2.2 Global PROteolysis Targeting Chimera (PROTAC) Forecasted Revenue by Application (2023-2028)
5.2.3 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Application (2017-2028)
5.3 Global PROteolysis Targeting Chimera (PROTAC) Price by Application
5.3.1 Global PROteolysis Targeting Chimera (PROTAC) Price by Application (2017-2022)
5.3.2 Global PROteolysis Targeting Chimera (PROTAC) Price Forecast by Application (2023-2028)
6 North America
6.1 North America PROteolysis Targeting Chimera (PROTAC) Market Size by Type
6.1.1 North America PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2028)
6.1.2 North America PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2028)
6.2 North America PROteolysis Targeting Chimera (PROTAC) Market Size by Application
6.2.1 North America PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2028)
6.2.2 North America PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2028)
6.3 North America PROteolysis Targeting Chimera (PROTAC) Market Size by Country
6.3.1 North America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2017-2028)
6.3.2 North America PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe PROteolysis Targeting Chimera (PROTAC) Market Size by Type
7.1.1 Europe PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2028)
7.1.2 Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2028)
7.2 Europe PROteolysis Targeting Chimera (PROTAC) Market Size by Application
7.2.1 Europe PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2028)
7.2.2 Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2028)
7.3 Europe PROteolysis Targeting Chimera (PROTAC) Market Size by Country
7.3.1 Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country (2017-2028)
7.3.2 Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Market Size by Type
8.1.1 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2028)
8.1.2 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2028)
8.2 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Market Size by Application
8.2.1 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2028)
8.2.2 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2028)
8.3 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Market Size by Region
8.3.1 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region (2017-2028)
8.3.2 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America PROteolysis Targeting Chimera (PROTAC) Market Size by Type
9.1.1 Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2028)
9.1.2 Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2028)
9.2 Latin America PROteolysis Targeting Chimera (PROTAC) Market Size by Application
9.2.1 Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2028)
9.2.2 Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2028)
9.3 Latin America PROteolysis Targeting Chimera (PROTAC) Market Size by Country
9.3.1 Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2017-2028)
9.3.2 Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Market Size by Type
10.1.1 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2028)
10.1.2 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2028)
10.2 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Market Size by Application
10.2.1 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2028)
10.2.2 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2028)
10.3 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Market Size by Country
10.3.1 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country (2017-2028)
10.3.2 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Arvinas
11.1.1 Arvinas Corporation Information
11.1.2 Arvinas Overview
11.1.3 Arvinas PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Arvinas PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Arvinas Recent Developments
11.2 Kymera
11.2.1 Kymera Corporation Information
11.2.2 Kymera Overview
11.2.3 Kymera PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Kymera PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Kymera Recent Developments
11.3 C4 therapeutics
11.3.1 C4 therapeutics Corporation Information
11.3.2 C4 therapeutics Overview
11.3.3 C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 C4 therapeutics Recent Developments
11.4 Captor therapeutics
11.4.1 Captor therapeutics Corporation Information
11.4.2 Captor therapeutics Overview
11.4.3 Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Captor therapeutics Recent Developments
11.5 Vividion
11.5.1 Vividion Corporation Information
11.5.2 Vividion Overview
11.5.3 Vividion PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Vividion PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Vividion Recent Developments
11.6 Cullgen
11.6.1 Cullgen Corporation Information
11.6.2 Cullgen Overview
11.6.3 Cullgen PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Cullgen PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Cullgen Recent Developments
11.7 Pfizer
11.7.1 Pfizer Corporation Information
11.7.2 Pfizer Overview
11.7.3 Pfizer PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Pfizer PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Pfizer Recent Developments
11.8 Merck
11.8.1 Merck Corporation Information
11.8.2 Merck Overview
11.8.3 Merck PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Merck PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Merck Recent Developments
11.9 Genentech
11.9.1 Genentech Corporation Information
11.9.2 Genentech Overview
11.9.3 Genentech PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Genentech PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Genentech Recent Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Corporation Information
11.10.2 AstraZeneca Overview
11.10.3 AstraZeneca PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 AstraZeneca PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 AstraZeneca Recent Developments
11.11 Amgen
11.11.1 Amgen Corporation Information
11.11.2 Amgen Overview
11.11.3 Amgen PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Amgen PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Amgen Recent Developments
11.12 Bayer
11.12.1 Bayer Corporation Information
11.12.2 Bayer Overview
11.12.3 Bayer PROteolysis Targeting Chimera (PROTAC) Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Bayer PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Bayer Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 PROteolysis Targeting Chimera (PROTAC) Industry Chain Analysis
12.2 PROteolysis Targeting Chimera (PROTAC) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 PROteolysis Targeting Chimera (PROTAC) Production Mode & Process
12.4 PROteolysis Targeting Chimera (PROTAC) Sales and Marketing
12.4.1 PROteolysis Targeting Chimera (PROTAC) Sales Channels
12.4.2 PROteolysis Targeting Chimera (PROTAC) Distributors
12.5 PROteolysis Targeting Chimera (PROTAC) Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 PROteolysis Targeting Chimera (PROTAC) Industry Trends
13.2 PROteolysis Targeting Chimera (PROTAC) Market Drivers
13.3 PROteolysis Targeting Chimera (PROTAC) Market Challenges
13.4 PROteolysis Targeting Chimera (PROTAC) Market Restraints
14 Key Findings in The Global PROteolysis Targeting Chimera (PROTAC) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global PROteolysis Targeting Chimera (PROTAC) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of ARV-110
Table 3. Major Manufacturers of ARV-471
Table 4. Major Manufacturers of KYM-001
Table 5. Major Manufacturers of Others
Table 6. Global PROteolysis Targeting Chimera (PROTAC) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global PROteolysis Targeting Chimera (PROTAC) Sales by Region (2017-2022) & (K Units)
Table 9. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Region (2017-2022)
Table 10. Global PROteolysis Targeting Chimera (PROTAC) Sales by Region (2023-2028) & (K Units)
Table 11. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Region (2023-2028)
Table 12. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Region (2017-2022)
Table 14. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Region (2023-2028)
Table 16. Global PROteolysis Targeting Chimera (PROTAC) Sales by Manufacturers (2017-2022) & (K Units)
Table 17. Global PROteolysis Targeting Chimera (PROTAC) Sales Share by Manufacturers (2017-2022)
Table 18. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global PROteolysis Targeting Chimera (PROTAC) Revenue Share by Manufacturers (2017-2022)
Table 20. PROteolysis Targeting Chimera (PROTAC) Price by Manufacturers (2017-2022) &(US$/Unit)
Table 21. Global PROteolysis Targeting Chimera (PROTAC) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global PROteolysis Targeting Chimera (PROTAC) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PROteolysis Targeting Chimera (PROTAC) as of 2021)
Table 23. PROteolysis Targeting Chimera (PROTAC) Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers PROteolysis Targeting Chimera (PROTAC) Product Offered
Table 25. Date of Manufacturers Enter into PROteolysis Targeting Chimera (PROTAC) Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2022) & (K Units)
Table 28. Global PROteolysis Targeting Chimera (PROTAC) Sales by Type (2023-2028) & (K Units)
Table 29. Global PROteolysis Targeting Chimera (PROTAC) Sales Share by Type (2017-2022)
Table 30. Global PROteolysis Targeting Chimera (PROTAC) Sales Share by Type (2023-2028)
Table 31. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global PROteolysis Targeting Chimera (PROTAC) Revenue Share by Type (2017-2022)
Table 34. Global PROteolysis Targeting Chimera (PROTAC) Revenue Share by Type (2023-2028)
Table 35. PROteolysis Targeting Chimera (PROTAC) Price by Type (2017-2022) & (US$/Unit)
Table 36. Global PROteolysis Targeting Chimera (PROTAC) Price Forecast by Type (2023-2028) & (US$/Unit)
Table 37. Global PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2022) & (K Units)
Table 38. Global PROteolysis Targeting Chimera (PROTAC) Sales by Application (2023-2028) & (K Units)
Table 39. Global PROteolysis Targeting Chimera (PROTAC) Sales Share by Application (2017-2022)
Table 40. Global PROteolysis Targeting Chimera (PROTAC) Sales Share by Application (2023-2028)
Table 41. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global PROteolysis Targeting Chimera (PROTAC) Revenue Share by Application (2017-2022)
Table 44. Global PROteolysis Targeting Chimera (PROTAC) Revenue Share by Application (2023-2028)
Table 45. PROteolysis Targeting Chimera (PROTAC) Price by Application (2017-2022) & (US$/Unit)
Table 46. Global PROteolysis Targeting Chimera (PROTAC) Price Forecast by Application (2023-2028) & (US$/Unit)
Table 47. North America PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2022) & (K Units)
Table 48. North America PROteolysis Targeting Chimera (PROTAC) Sales by Type (2023-2028) & (K Units)
Table 49. North America PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2022) & (K Units)
Table 52. North America PROteolysis Targeting Chimera (PROTAC) Sales by Application (2023-2028) & (K Units)
Table 53. North America PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2017-2022) & (K Units)
Table 56. North America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2023-2028) & (K Units)
Table 57. North America PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2022) & (K Units)
Table 60. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Type (2023-2028) & (K Units)
Table 61. Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2022) & (K Units)
Table 64. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Application (2023-2028) & (K Units)
Table 65. Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country (2017-2022) & (K Units)
Table 68. Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country (2023-2028) & (K Units)
Table 69. Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2022) & (K Units)
Table 72. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Type (2023-2028) & (K Units)
Table 73. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2022) & (K Units)
Table 76. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Application (2023-2028) & (K Units)
Table 77. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region (2017-2022) & (K Units)
Table 80. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region (2023-2028) & (K Units)
Table 81. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2022) & (K Units)
Table 84. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Type (2023-2028) & (K Units)
Table 85. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2022) & (K Units)
Table 88. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Application (2023-2028) & (K Units)
Table 89. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2017-2022) & (K Units)
Table 92. Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country (2023-2028) & (K Units)
Table 93. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Type (2017-2022) & (K Units)
Table 96. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Type (2023-2028) & (K Units)
Table 97. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Application (2017-2022) & (K Units)
Table 100. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Application (2023-2028) & (K Units)
Table 101. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country (2017-2022) & (K Units)
Table 104. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country (2023-2028) & (K Units)
Table 105. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Country (2023-2028) & (US$ Million)
Table 107. Arvinas Corporation Information
Table 108. Arvinas Description and Major Businesses
Table 109. Arvinas PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 110. Arvinas PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Arvinas Recent Developments
Table 112. Kymera Corporation Information
Table 113. Kymera Description and Major Businesses
Table 114. Kymera PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 115. Kymera PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Kymera Recent Developments
Table 117. C4 therapeutics Corporation Information
Table 118. C4 therapeutics Description and Major Businesses
Table 119. C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 120. C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. C4 therapeutics Recent Developments
Table 122. Captor therapeutics Corporation Information
Table 123. Captor therapeutics Description and Major Businesses
Table 124. Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 125. Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Captor therapeutics Recent Developments
Table 127. Vividion Corporation Information
Table 128. Vividion Description and Major Businesses
Table 129. Vividion PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 130. Vividion PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Vividion Recent Developments
Table 132. Cullgen Corporation Information
Table 133. Cullgen Description and Major Businesses
Table 134. Cullgen PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 135. Cullgen PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Cullgen Recent Developments
Table 137. Pfizer Corporation Information
Table 138. Pfizer Description and Major Businesses
Table 139. Pfizer PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 140. Pfizer PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Pfizer Recent Developments
Table 142. Merck Corporation Information
Table 143. Merck Description and Major Businesses
Table 144. Merck PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 145. Merck PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Merck Recent Developments
Table 147. Genentech Corporation Information
Table 148. Genentech Description and Major Businesses
Table 149. Genentech PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 150. Genentech PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Genentech Recent Developments
Table 152. AstraZeneca Corporation Information
Table 153. AstraZeneca Description and Major Businesses
Table 154. AstraZeneca PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 155. AstraZeneca PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. AstraZeneca Recent Developments
Table 157. Amgen Corporation Information
Table 158. Amgen Description and Major Businesses
Table 159. Amgen PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 160. Amgen PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Amgen Recent Developments
Table 162. Bayer Corporation Information
Table 163. Bayer Description and Major Businesses
Table 164. Bayer PROteolysis Targeting Chimera (PROTAC) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 165. Bayer PROteolysis Targeting Chimera (PROTAC) Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Bayer Recent Developments
Table 167. Key Raw Materials Lists
Table 168. Raw Materials Key Suppliers Lists
Table 169. PROteolysis Targeting Chimera (PROTAC) Distributors List
Table 170. PROteolysis Targeting Chimera (PROTAC) Customers List
Table 171. PROteolysis Targeting Chimera (PROTAC) Market Trends
Table 172. PROteolysis Targeting Chimera (PROTAC) Market Drivers
Table 173. PROteolysis Targeting Chimera (PROTAC) Market Challenges
Table 174. PROteolysis Targeting Chimera (PROTAC) Market Restraints
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. PROteolysis Targeting Chimera (PROTAC) Product Picture
Figure 3. Global PROteolysis Targeting Chimera (PROTAC) Market Share by Type in 2021 & 2028
Figure 3. ARV-110 Product Picture
Figure 4. ARV-471 Product Picture
Figure 5. KYM-001 Product Picture
Figure 6. Others Product Picture
Figure 7. Global PROteolysis Targeting Chimera (PROTAC) Market Share by Application in 2021 & 2028
Figure 8. Oncology
Figure 9. Others
Figure 10. PROteolysis Targeting Chimera (PROTAC) Report Years Considered
Figure 11. Global PROteolysis Targeting Chimera (PROTAC) Sales 2017-2028 (K Units)
Figure 12. Global PROteolysis Targeting Chimera (PROTAC) Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global PROteolysis Targeting Chimera (PROTAC) Revenue 2017-2028 (US$ Million)
Figure 14. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Region (2017-2022)
Figure 16. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Region (2023-2028)
Figure 17. North America PROteolysis Targeting Chimera (PROTAC) Sales YoY (2017-2028) & (K Units)
Figure 18. North America PROteolysis Targeting Chimera (PROTAC) Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe PROteolysis Targeting Chimera (PROTAC) Sales YoY (2017-2028) & (K Units)
Figure 20. Europe PROteolysis Targeting Chimera (PROTAC) Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific PROteolysis Targeting Chimera (PROTAC) Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America PROteolysis Targeting Chimera (PROTAC) Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa PROteolysis Targeting Chimera (PROTAC) Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The PROteolysis Targeting Chimera (PROTAC) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of PROteolysis Targeting Chimera (PROTAC) in the World: Market Share by PROteolysis Targeting Chimera (PROTAC) Revenue in 2021
Figure 29. Global PROteolysis Targeting Chimera (PROTAC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2017-2028)
Figure 31. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Type (2017-2028)
Figure 32. Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2017-2028)
Figure 33. Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Application (2017-2028)
Figure 34. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2017-2028)
Figure 35. North America PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Type (2017-2028)
Figure 36. North America PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2017-2028)
Figure 37. North America PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Application (2017-2028)
Figure 38. North America PROteolysis Targeting Chimera (PROTAC) Sales Share by Country (2017-2028)
Figure 39. North America PROteolysis Targeting Chimera (PROTAC) Revenue Share by Country (2017-2028)
Figure 40. United States PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 41. Canada PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 42. Europe PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2017-2028)
Figure 43. Europe PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Type (2017-2028)
Figure 44. Europe PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2017-2028)
Figure 45. Europe PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Application (2017-2028)
Figure 46. Europe PROteolysis Targeting Chimera (PROTAC) Sales Share by Country (2017-2028)
Figure 47. Europe PROteolysis Targeting Chimera (PROTAC) Revenue Share by Country (2017-2028)
Figure 48. Germany PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 49. France PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 51. Italy PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 52. Russia PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales Share by Region (2017-2028)
Figure 58. Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue Share by Region (2017-2028)
Figure 59. China PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 60. Japan PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 62. India PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 63. Australia PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2017-2028)
Figure 69. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Type (2017-2028)
Figure 70. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2017-2028)
Figure 71. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Application (2017-2028)
Figure 72. Latin America PROteolysis Targeting Chimera (PROTAC) Sales Share by Country (2017-2028)
Figure 73. Latin America PROteolysis Targeting Chimera (PROTAC) Revenue Share by Country (2017-2028)
Figure 74. Mexico PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 77. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2017-2028)
Figure 78. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Type (2017-2028)
Figure 79. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2017-2028)
Figure 80. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Application (2017-2028)
Figure 81. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales Share by Country (2017-2028)
Figure 82. Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue Share by Country (2017-2028)
Figure 83. Turkey PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 84. Saudi Arabia PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 85. UAE PROteolysis Targeting Chimera (PROTAC) Revenue (2017-2028) & (US$ Million)
Figure 86. PROteolysis Targeting Chimera (PROTAC) Value Chain
Figure 87. PROteolysis Targeting Chimera (PROTAC) Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed
$4900
$7350
$9800
HAVE A QUERY?
OUR CUSTOMER
